214 related articles for article (PubMed ID: 24947797)
1. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
[TBL] [Abstract][Full Text] [Related]
3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
4. The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.
Han X; Wang J; Zhang N; Yao J; Feng Y; Li D; Liu P; Yang J; Zhou S; Qin Y; Yang S; Gui L; He X; Shi Y
Leuk Res; 2014 Nov; 38(11):1291-8. PubMed ID: 25287608
[TBL] [Abstract][Full Text] [Related]
5. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma.
Wei X; Huang F; Wei Y; Jing H; Xie M; Hao X; Feng R
Leuk Res; 2014 Jun; 38(6):694-8. PubMed ID: 24713260
[TBL] [Abstract][Full Text] [Related]
6. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
8. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.
Witzig TE; Maurer MJ; Stenson MJ; Allmer C; Macon W; Link B; Katzmann JA; Gupta M
Am J Hematol; 2014 Apr; 89(4):417-22. PubMed ID: 24382707
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].
Wang KL; Chen C; Shi PF; Yu JH; Tan JF; Qian SX; Gao DQ; Chen K; Liu LR; Xie YP; Xu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1079-1085. PubMed ID: 30111411
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
Jardin F; Delfau-Larue MH; Molina TJ; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Jais JP; Figeac M; Leroy K; Mareschal S; Salles GA; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Haioun C; Tilly H
Leuk Lymphoma; 2013 Sep; 54(9):1898-907. PubMed ID: 23327290
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma.
Alacacioglu I; Ozcan MA; Ozkal S; Piskin O; Turgut N; Demirkan F; Ozsan GH; Kargi A; Undar B
Hematology; 2009 Apr; 14(2):84-9. PubMed ID: 19298719
[TBL] [Abstract][Full Text] [Related]
13. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
14. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies?
Beetham R; Wassell J; Wallage MJ; Whiteway AJ; James JA
Ann Clin Biochem; 2007 Nov; 44(Pt 6):516-22. PubMed ID: 17961305
[TBL] [Abstract][Full Text] [Related]
15. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different immunohistochemical algorithms identifying prognostic subgroups of DLBCL.
Jabłońska J; Jesionek-Kupnicka D; Potemski P; Kowalik A; Sygut J; Kordek R
Pol J Pathol; 2010; 61(3):124-32. PubMed ID: 21225494
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
18. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
19. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
Mitrovic Z; Ilic I; Nola M; Aurer I; Sonicki Z; Basic-Kinda S; Radman I; Ajdukovic R; Labar B
Clin Lymphoma Myeloma; 2009 Apr; 9(2):133-7. PubMed ID: 19406723
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
